CHUV, Centre Hospitalier Vaudois
Lausanne, Canton of Vaud, 1000, Switzerland
Location contact
Eric Albrecht, Prof.
CONTACT
Iliana Mrazek
CONTACT
NCT Number: NCT07666009
Rebound pain after peripheral nerve blocks reduces the benefits of regional anesthesia and increases opioid consumption. This rebound pain most likely results from suboptimal pain management, as patients receiving a peripheral nerve block are typically not given scheduled opioid doses. Oral Patient Controlled Analgesia (PCA) consists of an oral morphine prescription that allows patients to self-administer doses based on their pain score.
This study will compare patients undergoing elective orthopaedic surgery under general anaesthesia or sedation with a peripheral nerve block, receiving oral morphine PCA either with or without additional scheduled oral morphine doses.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Lausanne, Canton of Vaud, 1000, Switzerland
Eric Albrecht, Prof.
CONTACT
Iliana Mrazek
CONTACT
This study contains two parts, one for the upper limb and one for the lower limb. Each part will be published independently.
This registration concerns the lower limb cohort.
Patients from each cohort (upper limb and lower limb) will be randomized into two groups of 25 patients each, for a total enrollment plan of 50 patients per cohort. After written informed consent, patients will be allocated to one of the two groups according to a computer-generated randomization list.
In the control group, morphine will be administered exclusively on demand via oral PCA,based on pain intensity assessed using a numeric rating scale (VAS > 4). For oral PCA, one10 mg morphine tablet is placed on the patient's bedside table by the nursing staff. When the patients experience pain, they may take the tablet autonomously and subsequently inform the nurse, who then prepares and places a new tablet at bedside for the next potential pain episode. No scheduled or prophylactic opioid administration will be provided in this group. The maximal allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.
In the intervention group, morphine will be administered at predefined regular intervals, starting immediately in the postoperative period in addition to the availability of oral PCA morphine as mentioned above. Scheduled doses of 20mg slow-release oral morphine will be given at fixed 12 hour intervals. Patients will therefore receive regular morphine to ensure continuous baseline analgesia while still having access to an additional tablet via oral PCA in case of breakthrough pain, following the same nursing procedure as in the control group.
In both groups, standardized multimodal analgesia will be provided
The primary objective of this study is to assess and compare the highest pain score within the first 24 postoperative hours between the two groups using the Visual Analog Scale (VAS). The secondary objective is to assess the effect of the intervention on postoperative pain and analgesic outcomes, including morphine consumption, pain scores, need for additional nerve blocks, incidence of chronic pain, duration of analgesia, postoperative side effects, complications, and hospital length of stay.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Morphine will be administered according to a scheduled regimen (20mg slow release oral morphine at fixed 12-hour intervals), with additional oral PCA on demand for breakthrough pain (VAS > 4), following the same bedside tablet procedure as in the control group. The maximum allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.
morphine will be administered according to a scheduled regimen (20mg slow-release oral morphine at fixed 12-hour intervals), with additional oral PCA on demand for breakthrough pain (VAS > 4), following the same bedside tablet procedure as in the control group. The maximum allowed dose through oral PCA will be 6 tablets (10mg each) per 24-hour period.
Time frame: 24 hours postoperatively
Highest postoperative pain score during the first 24 hours after surgery, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable
Time frame: 12 hours postoperatively
Lowest postoperative pain score during the first 12 hours after surgery, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable
Time frame: From surgery until 24 hours postoperatively
Rebound pain score calculated as the difference between the highest postoperative pain score within the first 24 hours after surgery and the lowest postoperative pain score within the first 12 hours after surgery. Pain intensity is assessed using a Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher rebound pain scores indicate greater pain rebound
Time frame: At 2, 12, 24, 36, 48, 60, and 72 hours after surgery
Rest and dynamic pain scores, measured using a 0-10 Visual Analogue Score (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable
Time frame: From surgery through 3 months after surgery
Pain evaluated at >7/10, measured using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst pain imaginable
Time frame: During the follow-up period from discharge till 4 weeks and 3 months
Incidence of persistent pain at 4 weeks and chronic pain at 3 months
Time frame: from admission until discharge from the recovery room, up to 2 hours
consumption in mg
Time frame: Day 1, 2 and 3 postoperatively
Consumption in mg administered by PCA
Time frame: Day 1, 2 and 3 postoperatively
Total consumption in mg
Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively
Presence of nausea or vomiting in the postoperative period
Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively
Presence of pruritus in the postoperative period
Time frame: At 2 hours, day 1, day 2 and day 3 postoperatively
Urinary retention requiring catheterisation
Time frame: At hospital discharge (typically within 5 days, according to our hospital's standard practice)
Duration of hospitalization, measured as the number of days from surgery (baseline) to hospital discharge. Higher values indicate longer hospital stays.
Time frame: On postoperative day 1, 2 and 3
Requirement for a new peripheral nerve block
Time frame: From the time the block is performed up to 36 hours after surgery
Time between block performance and the first dose of morphine
Contact information is provided by the study sponsor or research team.
Eric Albrecht, Prof.
CONTACT
Iliana Mrazek
CONTACT
Centre Hospitalier Universitaire Vaudois
Other
Prevention of Rebound Pain After Orthopaedic Surgery With Peripheral Nerve Block: a Single-blinded Randomised Controlled Trial
Acronym: REBOUND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07666971
Agnosia, Nervous System Diseases
Lausanne, Switzerland
View Trial DetailsNCT07502235
Agnosia, Cesarean Birth
Cairo, Egypt
View Trial DetailsNCT07109388
Hip Arthroplasty Replacement, Neurologic Manifestations
View Trial DetailsNCT06923540
Abdominal Surgeries, Acetaminophen
Montreal, Quebec, Canada
View Trial Details